Inflammation and hemostasis in loiasis before and after ivermectin treatment: A biological pilot cross-sectional study Authors: Tristan M. Lepage, Narcisse Nzune-Toche, Lucie A. Nkwengoua, Hugues C. Nana-Djeunga, Sebastien D. S. Pion, Joseph Kamgno, Charlotte Boullé, Jérémy T. Campillo, Michel Boussinesq, Claude T. Tayou, Cédric B. Chesnais, jong-Yil Chai, Feng Xue, jong-Yil Chai, Feng Xue, jong-Yil Chai, Feng Xue Published: 2024 ABSTRACT We assessed the impact of loiasis and its treatment with ivermectin on hemostasis and inflammation in 38 adults in Cameroon. Participants were divided into four balanced groups based on their Loa loa microfilarial densities. At baseline, eosinophils and platelets increased with microfilarial densities (p<0.001 and p = 0.044, respectively). At day 4 following ivermectin administration, median eosinophils rose from 171/μL to 1,095/μL (p<0.001) and median D-dimers increased from 582 ng/mL to 745 ng/mL (p = 0.024) with a median relative variation of +34.7%. C-reactive protein, fibrinogen, and alpha-1-globulin also increased significantly after treatment. Ivermectin treatment appeared to induce inflammation, coagulation activation and fibrinolysis. Background Loiasis, caused by the filarial nematode Loa loa and transmitted from human to human by tabanids, is exclusively endemic in central Africa. In infected individuals, adult female worms release embryos called microfilariae (mfs) which circulate in the bloodstream according to a diurnal cycle, with densities occasionally surpassing 100,000 mfs per mL of blood (mf/mL). Although loiasis is historically considered as a benign disease, recent findings suggest that microfilaremic individuals have a significantly shortened life expectancy [1]. In addition, studies in the Republic of Congo showed that high L. loa microfilarial density (MFD) was significantly associated with proteinuria [2], cognitive impairment [3], and increased vascular stiffness [4]. Eosinophilia exceeding 5,000 /μL is common among subjects with loiasis. Eosinophils, known to express tissue factor, may trigger blood coagulation [5], leading to thrombosis. Reports indicate that arterial and venous thrombotic events can occur in patients with parasite-related hypereosinophilia [6], with documented instances of thrombosis [7] and micro-emboli formation in capillary vessels [8], occurring both spontaneously and as part of post-ivermectin (IVM) Loa-related serious adverse events (SAEs). Indeed, IVM mass drug administration in onchocerciasis endemic regions may cause SAEs such as life-threatening encephalopathies in patients with high L. loa MFD above 30,000 mf/mL, due to its potent microfilaricidal effect [9]. Evidence from primate models suggests an association between post-IVM encephalopathy and hemostatic dysregulation, characterized by degenerating mfs in small vessels associated with fibrin deposition, endothelial damages, and hemorrhages [10]. Similarly, humans experiencing post-ivermectin encephalopathy often exhibit conjunctival and retinal hemorrhages [11]. A potential dysregulation of hemostasis may contribute to the excess morbidity and mortality associated with loiasis and its treatment with IVM. However, data on this phenomenon remains limited and unexplored in humans. The objective of the present study was to assess for the first time the impact of both L. loa MFD and IVM on human hemostasis and inflammation blood parameters. Methods Ethics statement The study adhered to ethical guidelines outlined in the Declaration of Helsinki, version 13, and was approved by the Ethics Committee for Human Research of the Catholic University of Central Africa (N° 2022/022503/CEIRSH/ESS/MH) and by Yaoundé University Teaching Hospital (N° 4181/AR/CHUY/DG/DGA/CAPRC). Only individuals who provided informed consent were enrolled and assigned an individual code for data recording. Blood parameters results were shared with all participants. Study design and participants The study was conducted from July to December 2022 in two Health Districts of the Center Region of Cameroon (Mbalmayo and Awaé) where loiasis is highly endemic. Participants consisted of consenting adults aged 25 to 70 who had been screened for L. loa mfs. Exclusion criteria included pregnancy, concurrent pro-inflammatory conditions (such as infection, cancer or hematological disorder), current use of anticoagulant or anti-inflammatory medications, or known allergy to IVM. Eligible participants were stratified into 4 groups based on their L. loa MFD: 0 mf/mL; 20–4,999 mf/mL; 5,000–19,999 mf/mL; and 20,000–40,000 mf/mL. Venous blood samples were collected from all groups at baseline (D0) to measure hematological, hemostatic, and biochemical parameters. Subsequently, individuals in the 20–4,999 mf/mL and 5,000–19,999 mf/mL groups received a single oral dose of IVM (150μg/kg), and the same blood parameters were reassessed four days after (D4) treatment. Sample size No data exists on the relationships between loiasis and hemostasis. In a study evaluating D-dimer levels in dogs infected with another filaria (Dirofilaria immitis) [12], the proportion of elevated D-dimers (>0.2 μg/ml) was 48% (22/46) in microfilaremic dogs, compared to 0% in amicrofilaremic dogs. Based on this finding, the inclusion of 16 L. loa microfilaremic subjects and 16 amicrofilaremic subjects would provide an 80% power with an alpha risk of 5% to detect such a difference in loiasis. However, it is difficult to extrapolate these assumptions to loiasis, which is a different disease with a different host. Therefore, we planned to include 10 L. loa amicrofilaremic subjects, and 30 microfilaremic subjects in 3 groups of ascending MFD. Laboratory analyses Blood was collected by fingerprick between 10:00 am and 3:00 pm in non-heparinized capillaries and spread on microscope slides to prepare two 50 μL thick blood smears which were dried, dehemoglobinized, and stained with Giemsa within 24 hours. L. loa mfs present on slides were counted using a microscope at 100-fold magnification at the Higher Institute for Scientific and Medical Research in Yaoundé, and averages of both slides were multiplied by 20 to express MFD per milliliter of blood. Venous blood samples were collected from each participant using EDTA, sodium citrate, and dry blood tubes. Complete blood counts (flow cytometry), erythrocyte sedimentation rate (ESR) after one-hour (Westergren method), C-reactive protein (CRP) levels assessed by nephelometry, prothrombin time (PT), activated thromboplastin time (aPTT) and fibrinogen levels (chronometry) were measured at the hematology laboratory of the Yaoundé University Teaching Hospital. Wright-stained blood smears were prepared, and the percentage of eosinophils was recorded after examining 200 leukocytes. Eosinophil counts were calculated by multiplying the percentage of eosinophils by the white blood cells count. Serum protein electrophoresis, ferritin (chemiluminescence) and D-dimers (ELISA) were assessed at the Centre Pasteur in Yaoundé. Finally, prothrombin fragment F1+2 (ELISA) and plasminogen activity (amidolytic method followed by nephelometry) were evaluated in a subset of participants (10 with no microfilariae and 10 with 20–40,000 mf/mL) at the Cerba Laboratory in France. Statistical analysis Hematological, hemostatic, and biochemical blood parameters were compared among the four MFD groups at baseline using the Kruskal-Wallis test. When the test yielded a p-value < 0.1, a Cuzick’s test for trend was performed. Since D-dimers levels can be influenced by age and sex, the relationship between D-dimer and MFD was also assessed using a linear regression, with adjustments on age and sex. Prothrombin fragment F1+2 and plasminogen, assessed in a subset of 20 participants, were compared between amicrofilaremic and microfilaremic subjects using the Wilcoxon rank-sum test. Finally, within the groups of individuals treated with IVM (20–4,999 mf/mL and 5,000–19,999 mf/mL), changes in hematological, hemostatic, and biochemical blood parameters were compared between baseline and D4 post-IVM using a Wilcoxon signed-rank test for paired observations. Results Twenty males and 18 females aged between 28 and 67 years (median age: 43 years old) participated in the study. Table 1 presents the blood counts and the inflammation and hemostasis parameters according to the participants’ L. loa MFD categories. There was a trend towards increased leucocyte, granulocyte and eosinophil counts with increasing MFD (p = 0.011, p = 0.013 and p<0.001, respectively, Cuzick’s tests for trend). Median eosinophil counts were significantly higher in patients with a MFD exceeding 20,000 mf/mL compared to those with no mf (1,016/μL vs 111/μL, p<0.001). Similarly, median platelet counts were also significantly higher in the same group (254,500/μL vs 180,000/μL, p = 0.044). Inflammation and hemostasis parameters did not significantly differ between groups. Linear regression analysis of D-dimers by MFD, adjusted on age and sex, did not show any significant associations. Median ESR were consistently increased across all groups (normal values: < 20 mm/h). Gamma-globulins were also elevated in all groups, with medians from 19 to 23 g/L (normal values: < 11 g/L). Clonal gamma-globulin expression was suspected in the serum protein electrophoresis in 3 patients, each in separate groups. 10.1371/journal.pntd.0012491.t001Table 1Blood count, inflammation, and hemostasis parameters according to L. loa microfilaremia.Characteristic0mf/mL, N = 1020–4,999mf/mL, N = 115,000–19,999mf/mL, N = 720,000–40,000mf/mL, N = 10p-valueSex1 Male5 (50%)6 (55%)3 (43%)4 (40%) Female5 (50%)5 (45%)4 (57%)6 (60%)Age (years)240 (38, 52)44 (41, 60)38 (38, 41)54 (43, 58) Blood count Hemoglobin (g/dl)212.60 (12.13, 13.00)12.90 (11.25, 13.35)13.10 (11.45, 14.85)11.70 (11.10, 12.58)0.681†Leucocytes (/μl)25,535 (4,770, 6,023)6,440 (5,315, 8,460)7,160 (6,400, 7,405)8,825 (6,410, 9,675)0.073†Granulocytes (/μl)22,300 (2,168, 3,793)3,320 (3,055, 5,405)3,670 (3,560, 4,215)5,680 (2,748, 6,635)0.078†Eosinophils (/μl)2111 (96, 121)129 (107, 199)330 (198, 454)1,016 (273, 1,806) <0.001 † Eosinophils (%)22.0 (2.0, 2.0)2.0 (2.0, 2.0)4.0 (2.5, 6.5)10.5 (4.5, 18.0) <0.001 † Lymphocytes (/μl)22,185 (1,795, 2,530)2,540 (1,605, 2,965)2,320 (2,205, 2,460)2,615 (2,325, 2,980)0.451†Platelets (/μl)2180,000 (163,250, 317,750)180,000 (116,500, 206,500)241,000 (217,000, 255,500)254,500 (198,500, 277,250) 0.044 † Inflammation CRP (mg/l)24 (3, 8)3 (3, 6)5 (4, 9)4 (3, 7)0.671†ESR (mm/h)253 (38, 85)53 (33, 82)58 (47, 98)70 (39, 91)0.791†Fibrinogen (g/l)22.70 (2.32, 2.91)2.50 (2.30, 3.22)2.54 (2.45, 3.54)2.52 (2.35, 3.12)0.710†Ferritin (μg/l)2131 (59, 269)213 (157, 284)269 (113, 350)250 (127, 357)0.569†Albumin (g/l)247 (40, 54)40 (38, 42)45 (38, 52)51 (43, 53)0.258†Alpha-1-Globulin (g/l)21.40 (1.10, 3.25)1.80 (1.70, 1.88)1.30 (1.15, 3.05)1.20 (1.00, 2.88)0.791†Alpha-2-Globulin (g/l)26.25 (4.45, 6.60)5.85 (4.48, 6.78)5.40 (4.70, 5.70)5.05 (4.63, 6.28)0.763†Beta-Globulin (g/l)26.60 (5.20, 8.10)6.75 (6.35, 7.30)6.50 (6.05, 8.25)5.85 (5.25, 7.60)0.851†Gamma-Globulin (g/l)219 (16, 28)23 (19, 28)21 (17, 25)19 (17, 26)0.664† Hemostasis PT (%)286 (79, 95)98 (81, 100)85 (82, 88)87 (77, 91)0.502†aPTT ratio20.95 (0.90, 0.96)0.92 (0.87, 1.05)0.98 (0.96, 1.05)0.93 (0.85, 1.09)0.420†D-Dimers (ng/ml)2561 (395, 1,005)587 (307, 858)577 (382, 624)634 (460, 1,223)0.765†F1+2* (pmol/l)2342 (252, 390)262 (252, 302)0.438‡Plasminogen (%)2100 (89, 118)100 (96, 110)0.970‡1 n (%)2 Median (IQR)*Prothrombin fragment 1+2†Kruskal-Wallis rank sum test‡Wilcoxon rank sum testReference ranges: Hemoglobin 12,0–17,4 g/dL; Leucocytes 5,000–10,000/μL; Granulocytes 2,500–7,500/μL; Eosinophils < 500/μL; Lymphocytes 1,300–4,000/μL; Platelets 150,000–400,000/μL; CRP < 5 mg/L; ESR < 20 mm/h; Fibrinogen 2.0–4.0 g/L; Ferritin 18–370 ng/mL; Albumin 43–51 g/L; Alpha-1-Globulin 1.0–2.0 g/L; Alpha-2-Globulin 5.0–8.0 g/L; Beta-Globulin 6.0–9.0 g/L; Gamma-Globulin 6.0–11.0 g/L; PT > 70%; aPTT ratio 0.8–1.2; D-Dimers < 500 ng/mL; F1+2 69–229 pmol/L; Plasminogen 75–140%. Blood count, inflammation, and hemostasis parameters according to L. loa microfilaremia. 1 n (%) 2 Median (IQR) *Prothrombin fragment 1+2 †Kruskal-Wallis rank sum test ‡Wilcoxon rank sum test Reference ranges: Hemoglobin 12,0–17,4 g/dL; Leucocytes 5,000–10,000/μL; Granulocytes 2,500–7,500/μL; Eosinophils < 500/μL; Lymphocytes 1,300–4,000/μL; Platelets 150,000–400,000/μL; CRP < 5 mg/L; ESR < 20 mm/h; Fibrinogen 2.0–4.0 g/L; Ferritin 18–370 ng/mL; Albumin 43–51 g/L; Alpha-1-Globulin 1.0–2.0 g/L; Alpha-2-Globulin 5.0–8.0 g/L; Beta-Globulin 6.0–9.0 g/L; Gamma-Globulin 6.0–11.0 g/L; PT > 70%; aPTT ratio 0.8–1.2; D-Dimers < 500 ng/mL; F1+2 69–229 pmol/L; Plasminogen 75–140%. Eighteen individuals with an MFD between 20 and 19,999 mf/mL received a single dose of IVM and were re-examined at D4 (Table 2). Post-treatment, the median MFD significantly decreased from 3,605 mf/mL to 1,810 mf/mL. Median eosinophil counts rose from 171/μL to 1,095/μL (p<0.001). Various inflammation markers changed significantly: CRP, ESR, fibrinogen and alpha-1-globulin levels increased (p = 0.038, p = 0.010, p = 0.002 and p = 0.044, respectively), while albumin level decreased p = 0.044). Among hemostatic parameters, median D-dimers significantly increased, from 582 ng/mL to 745 ng/mL after IVM (p = 0.024) with a median relative variation of +34.7% (interquartile range: 1.44–72.5%). Prothrombin fragment 1+2 did not significantly vary (252 versus 469 pmol/L, p = 0.313). No new clonal gamma-globulin expression on protein electrophoresis was suspected, while previously identified clonal expression in treated patients did not change after IVM. 10.1371/journal.pntd.0012491.t002Table 2Blood count, inflammation, and hemostasis parameters at baseline and 4 days after IVM treatment in patients with L. loa microfilaremia.CharacteristicBaseline, N = 18D4 after IVM, N = 18p-value2MFD* (mf/mL) 13,605 (1,645, 10,020)1,810 (545, 2,933) Blood count Hemoglobin (g/dl) 112.90 (11.08, 14.00)11.80 (9.65, 13.60)0.058Leucocytes (/μl) 16,600 (5,853, 7,460)7,070 (5,975, 9,598)0.119Granulocytes (/μl) 13,635 (3,138, 4,758)4,010 (2,165, 6,253)0.417Eosinophils (/μl) 1171 (121, 239)1,095 (281, 2,179) <0.001 Eosinophils (%)12 (2, 3)20 (5, 31) <0.001 Lymphocytes (/μl) 12,460 (2,103, 2,648)2,385 (1,723, 3,218)0.663Platelets (/μl) 1213,000 (170,250, 240,750)187,000 (156,750, 217,750)0.170 Inflammation CRP (mg/l) 15 (3, 6)10 (3, 15) 0.038 ESR (mm/h) 156 (40, 92)81 (60, 97) 0.010 Fibrinogen (g/l) 12.52 (2.35, 3.58)3.14 (2.63, 3.76) 0.002 Ferritin (μg/l) 1234 (138, 337)224 (120, 366)0.089Albumin (g/l) 141 (38, 47)39 (36, 44) 0.044 Alpha-1-Globulin (g/l) 11.80 (1.30, 2.80)1.95 (1.73, 3.48) 0.044 Alpha-2-Globulin (g/l) 15.40 (4.60, 6.50)5.80 (5.08, 6.60)0.255Beta-Globulin (g/l) 16.60 (6.20, 7.90)6.70 (6.23, 8.25)0.842Gamma-Globulin (g/l) 121 (19, 26)22 (19, 26)0.831 Hemostasis PT (%)188 (81, 100)96 (86, 100)0.220aPTT ratio10.97 (0.92, 1.05)0.99 (0.90, 1.08)0.257D-Dimers (ng/ml)1582 (352, 820)745 (512, 1,061) 0.024 F1+2† (pmol/l) 1252 (242, 290) (N = 6)469 (334, 529) (N = 7)0.313Plasminogen (%)1100 (96, 107) (N = 7)90 (85, 102) (N = 6)0.4381 Median (IQR)2 Wilcoxon signed-rank test* Microfilarial density†Prothrombin fragment 1+2Reference ranges: Hemoglobin 12,0–17,4 g/dL; Leucocytes 5,000–10,000/μL; Granulocytes 2,500–7,500/μL; Eosinophils < 500/μL; Lymphocytes 1,300–4,000/μL; Platelets 150,000–400,000/μL; CRP < 5 mg/L; ESR < 20 mm/h; Fibrinogen 2.0–4.0 g/L; Ferritin 18–370 ng/mL; Albumin 43–51 g/L; Alpha-1-Globulin 1.0–2.0 g/L; Alpha-2-Globulin 5.0–8.0 g/L; Beta-Globulin 6.0–9.0 g/L; Gamma-Globulin 6.0–11.0 g/L; PT > 70%; aPTT ratio 0.8–1.2; D-Dimers < 500 ng/mL; F1+2 69–229 pmol/L; Plasminogen 75–140%. Blood count, inflammation, and hemostasis parameters at baseline and 4 days after IVM treatment in patients with L. loa microfilaremia. 1 Median (IQR) 2 Wilcoxon signed-rank test * Microfilarial density †Prothrombin fragment 1+2 Reference ranges: Hemoglobin 12,0–17,4 g/dL; Leucocytes 5,000–10,000/μL; Granulocytes 2,500–7,500/μL; Eosinophils < 500/μL; Lymphocytes 1,300–4,000/μL; Platelets 150,000–400,000/μL; CRP < 5 mg/L; ESR < 20 mm/h; Fibrinogen 2.0–4.0 g/L; Ferritin 18–370 ng/mL; Albumin 43–51 g/L; Alpha-1-Globulin 1.0–2.0 g/L; Alpha-2-Globulin 5.0–8.0 g/L; Beta-Globulin 6.0–9.0 g/L; Gamma-Globulin 6.0–11.0 g/L; PT > 70%; aPTT ratio 0.8–1.2; D-Dimers < 500 ng/mL; F1+2 69–229 pmol/L; Plasminogen 75–140%. Discussion In this pilot biological study, we describe for the first time hemostasis and inflammation parameters associated with loiasis. Our results show a remarkable trend towards increased leukocytes and granulocytes, mainly driven by elevated eosinophils, with increasing L. loa MFD. In a 2022 biological study in Gabon [13], eosinophil counts were also positively correlated with L. loa MFD, with an estimated increase in eosinophil counts every 10-fold increase in parasitemia (p-adj. = 0.012, ß-estimate: 0.17[0.04–0.31]). Chronic eosinophilia, a characteristic feature of loiasis, is known for its ability to trigger severe health conditions, such as endomyocardial fibrosis, tropical pulmonary eosinophilia, and thromboembolic events, consequently increasing the risk of mortality associated with loiasis [1]. The notable increase in platelets with increasing MFDs suggests their probable role in filarial infections. Prior research has established that platelets mediate the immunological killing of L. loa mfs [14,15], while data in lymphatic filariasis also demonstrated mfs’ ability to modulate platelet functions [16]. Furthermore, our study highlighted a polyclonal elevation of gamma-globulins across all MFD groups, suggesting a systemic immune response. This phenomenon is consistent with a previous study in Ghana, were 75% of participants had gamma-globulins > 16 g/L [17]. This hypergammaglobulinemia might be explained by the influence of genetic as well as environmental factors. ESR were increased in all groups, possibly driven by hypergammaglobulinemia, which is known to accelerate erythrocyte sedimentation. Interestingly, while inflammation and hemostasis parameters did not significantly vary with L. loa MFD at baseline, treatment with IVM resulted in significant alterations in several inflammatory markers (such as CRP, ESR, fibrinogen, albumin and alpha-1-globulins). While post-IVM CRP increase has been reported previously [18], we document for the first time significant changes in a range of inflammatory parameters. We observed a marked increase in eosinophils, consistent with previous reports of interleukin-5 (IL-5)-driven eosinophilia following microfilarial killing by IVM [19]. The increase in D-dimers observed on D4 post-IVM suggests both enhanced fibrinolysis and coagulation activation which happen simultaneously. This could be attributed to the close relationship between hemostasis and inflammation, where inflammation induces fibrin formation in the extravascular space, facilitating immune cells functions [20]. Consequently, secondary fibrinolysis generates D-dimers, which correlate with inflammation severity. However, this correlation is modest, as previous studies found a Spearman’s correlation coefficient of 0.18 between CRP and D-dimers, indicating a limited response of D-dimers to CRP elevation [21]. Therefore, in addition to inflammation, the potential involvement of thrombotic processes in the increase of D-dimers after IVM cannot be ruled out, potentially both driven by intravascular dying mfs and inflammation-induced hypercoagulable condition. In addition to previous reports of post-IVM retinal emboli [11], this hypothesis is supported by autopsies of post-IVM encephalopathies in baboon models, which show abnormalities ranging from intravascular degenerating mfs and vessel wall infiltration by immune cells such as eosinophils, to fibrin deposition and endothelial disruption with extravascular hemosiderin deposits [10,22]. These findings provide a plausible pathological basis for the observed post-IVM treatment biological changes, potentially contributing to the pathogenesis of post-IVM SAEs. Despite the valuable insights gained, our study has limitations. The small sample size and absence of preexisting data require cautious interpretation of our findings, highlighting the need for larger dedicated studies to validate our observations and understand their clinical implications. However, our results, particularly in baseline comparisons, may guide further research with adequate sample sizes, especially to explore the impact of loiasis on the hemostatic system. Additionally, potential confounding by other health conditions among participants, particularly in a low-resource healthcare setting, warrants consideration. Despite this, hematological changes showed a significant increase trend with L. loa MFD, aligning with previous findings [13]. However, as only L. loa MFD was assessed, potential confounding by other parasitic infections sensitive to IVM cannot be ruled out. Finally, our reliance on a single post-IVM evaluation timepoint may have limited our ability to detect biological abnormalities occurring outside this timeframe. In conclusion, this pilot study identified several biological changes potentially associated with loiasis, occurring both spontaneously and after treatment with IVM. Further dedicated studies are needed to confirm these results, which might participate in loiasis excess mortality as well as post-IVM SAEs pathogenesis. 4 Oct 2024 Dear Dr. Lepage, Thank you very much for submitting your manuscript "Inflammation and fibrinolysis in loiasis before and after ivermectin treatment: a biological pilot cross-sectional study" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments. We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation. When you are ready to resubmit, please upload the following: [1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. [2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file). Important additional instructions are given below your reviewer comments. Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts. Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments. Sincerely, Feng Xue, Ph.D. Guest Editor PLOS Neglected Tropical Diseases Jong-Yil Chai Section Editor PLOS Neglected Tropical Diseases *********************** Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: The article does not clearly state why ivermectin therapy was chosen. The introduction should clearly state the specific advantages of this therapy over others. Authors should indicate whether each type of loiasis treatment is associated with hemostatic disorders, or whether this is specific for the ivermectin therapy only. It is a bit confusing, why patients with the highest MFD count (20,000-40,000) did not receive the treatment. Reviewer #2: (No Response) Reviewer #3: In concerns a pilot study with appropriate design. -------------------- Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: Elevation of d-dimers, observed in this work, is an indirect sign of the hemostasis dysregulation. In order to evaluate the patients’ hemostasis state, global hemostasis test, sensitive to both hypo- and hyper-coagulation, like thrombin generation test, or thrombodynamics, should be assessed. Reviewer #2: (No Response) Reviewer #3: -The authors describe an elevation of neutrophils in the results section, however only granulocytes are depicted in table 1. Can the authors add the neutrophil counts here? -In the first paragraph of the results section, the authors describe that ‘there was a trend towards increased leucocytes, neutrophils and eosinophils’. However, for eosinophils this is not only a trend, but a highly significant elevation. The text should be adjusted to make this more clear. -Platelets are significantly lower in 20-4,999 mf/mL group. Can the authors discuss on these findings? -------------------- Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: The conclusion (inflammation activation and pronounced fibrinolysis, indicative of coagulation activation) is mainly based on elevation of neutrophils and eosinophils, as well as D-dimer levels. More specific markers need to be included to be able to conclude this. -------------------- Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: Modifications are mentioned in the other sections. -------------------- Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: (No Response) Reviewer #2: Lepage et al. report an observational study in patients with loasis, in whom markers of inflammation and coagulation were measured. They observed that eosinophils increased with MFD. In a subgroup that received ivermectin treatment, an increase of eosinophils was also associated with an increase in inflammatory parameters and D-dimer. This is an interesting study, whose results improves the understanding of loasis. Major comments: 1. I find it difficult to understand, what is the authors’ main interpretation of d-dimer changes. The abstract suggests that it is increased fibrinolysis. “Ivermectin… appeared to induce… pronounced fibrinolysis” (line 29,30). The paragraph about d-dimer changes in the discussion (line 176 ff) also starts with an interpretation of increased d-dimer as an indicator of increased fibrinolysis, then suggests that it might be indicative of increased thrombus formation / hypercoagulability. This is confusing, as a “pronounced fibrinolysis” would imply a bleeding phenotype. D-dimer is a compound biomarker of increased coagulation activation AND fibrinolysis activation which happen simultaneously. It is not a fibrinolysis biomarker, and – in the absence of other findings – is not indicative of thrombotic processes. 2. Laboratory analyses should be described in more detail. Information regarding reagents and analyzers should be provided. The method of fibrinogen measurement should be provided (Clauss method?). 3. Statistical analysis. Were the data tested for normality? Data are presented as mean and SD, but non-parametric tests were used to compare groups. Generally, normally distributed data should be presented as mean and SD, otherwise it is usually presented as median and IQR. Normally distributed data should be compared using parametric tests. 4. Presentation of results. Reference ranges for parameters should be provided in the tables. Age and sex of the study participants in each of the four cohorts should be provided in Table1. In Table 2, MFD at baseline and at D4 after treatment should be provided. The terms neutrophils or granulocytes should be used consistently. Some figures, e.g. box plots, or scatter plots for possible correlations should be considered. Minor comments: 5. Abstract. Use of the term “correlation” wrongly suggests Spearman or Pearson analysis, when the observation in fact is, that granulocytes increase with MFD. 6. The introduction should include background information regarding ivermectin. 7. Why did the group with the highest MFD not received ivermectin treatment? 8. Line 144, it should not be stated that F1+2 increased, as the p-value was quite high, and the number of patients (n=7) was small. Reviewer #3: Tristan Lepage and colleagues have investigated the impact of loiasis and its treatment with ivermectin on hemostasis and inflammation. It concerns a pilot study with a limited number of participants, and differences were observed in some general inflammation and hemostasis parameters. For me, the analyzed parameters are too general and conclusions are drawn by elevation of some of these parameters. -Most importantly, coagulation activation is now suggested based on elevated D-dimer levels. Better markers, for examples TAT-complexes, should be provided to be able to demonstrate coagulation activation. -Eligible participants for this study, screened for the presence of L. loa mfs, were stratified into 4 groups based on their MFD. However, how is it then possible to have a group with 0 mf/mL? -Measuring von Willebrand factor antigen levels would be of added value for this study to demonstrate a dysregulation of hemostasis. -An elevation of neutrophils is observed, and the authors aim to link L. loa to hemostasis and thrombosis. A discussion on the possible involvement of neutrophils extracellular traps (NETs; related to their role in coagulation activation) would be in place. -------------------- PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No Figure Files: While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Data Requirements: Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5. Reproducibility: To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols 26 Nov 2024 Submitted filename: Review PLOS NTD HECOLO v2.docx 2 Dec 2024 Dear Dr. Lepage, We are pleased to inform you that your manuscript 'Inflammation and hemostasis in loiasis before and after ivermectin treatment: a biological pilot cross-sectional study' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases. Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests. Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated. IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript. Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS. Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Feng Xue, Ph.D. Guest Editor PLOS Neglected Tropical Diseases Jong-Yil Chai Section Editor PLOS Neglected Tropical Diseases Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-4304-636XX Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases orcid.org/0000-0003-1765-0002 *********************************************************** Reviewer's Responses to Questions Key Review Criteria Required for Acceptance? As you describe the new analyses required for acceptance, please consider the following: Methods -Are the objectives of the study clearly articulated with a clear testable hypothesis stated? -Is the study design appropriate to address the stated objectives? -Is the population clearly described and appropriate for the hypothesis being tested? -Is the sample size sufficient to ensure adequate power to address the hypothesis being tested? -Were correct statistical analysis used to support conclusions? -Are there concerns about ethical or regulatory requirements being met? Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: (No Response) ********** Results -Does the analysis presented match the analysis plan? -Are the results clearly and completely presented? -Are the figures (Tables, Images) of sufficient quality for clarity? Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: (No Response) ********** Conclusions -Are the conclusions supported by the data presented? -Are the limitations of analysis clearly described? -Do the authors discuss how these data can be helpful to advance our understanding of the topic under study? -Is public health relevance addressed? Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: (No Response) ********** Editorial and Data Presentation Modifications? Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend “Minor Revision” or “Accept”. Reviewer #1: (No Response) Reviewer #2: (No Response) Reviewer #3: (No Response) ********** Summary and General Comments Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed. Reviewer #1: My comments have been addressed. It is acceptable in the present form. Reviewer #2: My concerns have been satisfactorily addressed. The manuscript now provides more clarity and scientific rigor. Reviewer #3: The authors have addressed all my comments appropriately and have addressed my concerns. ********** PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No 10 Dec 2024 Dear Dr. Lepage, We are delighted to inform you that your manuscript, "Inflammation and hemostasis in loiasis before and after ivermectin treatment: a biological pilot cross-sectional study," has been formally accepted for publication in PLOS Neglected Tropical Diseases. We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication. The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc...) are generated on a different schedule and may not be made available as quickly. Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers. Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases. Best regards, Shaden Kamhawi co-Editor-in-Chief PLOS Neglected Tropical Diseases Paul Brindley co-Editor-in-Chief PLOS Neglected Tropical Diseases